A detailed history of Quantinno Capital Management LP transactions in Amgen Inc stock. As of the latest transaction made, Quantinno Capital Management LP holds 131,245 shares of AMGN stock, worth $37.8 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
131,245
Previous 124,004 5.84%
Holding current value
$37.8 Million
Previous $38.7 Million 9.14%
% of portfolio
0.56%
Previous 0.71%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$309.38 - $337.38 $2.24 Million - $2.44 Million
7,241 Added 5.84%
131,245 $42.3 Million
Q2 2024

Aug 14, 2024

BUY
$262.75 - $319.31 $499,487 - $607,008
1,901 Added 1.56%
124,004 $38.7 Million
Q1 2024

May 14, 2024

BUY
$268.87 - $324.56 $649,858 - $784,461
2,417 Added 2.02%
122,103 $34.7 Million
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $888,046 - $1 Million
3,473 Added 2.99%
119,686 $34.5 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $6.92 Million - $8.59 Million
31,627 Added 37.39%
116,213 $31.2 Million
Q2 2023

Aug 04, 2023

SELL
$214.27 - $253.37 $3.44 Million - $4.07 Million
-16,046 Reduced 15.95%
84,586 $18.8 Million
Q1 2023

May 03, 2023

SELL
$225.79 - $275.2 $1.62 Million - $1.98 Million
-7,177 Reduced 6.66%
100,632 $24.3 Million
Q4 2022

Feb 13, 2023

BUY
$229.03 - $291.01 $23.1 Million - $29.3 Million
100,738 Added 1424.66%
107,809 $28.3 Million
Q3 2022

Nov 07, 2022

BUY
$224.46 - $253.15 $824,217 - $929,566
3,672 Added 108.03%
7,071 $1.59 Million
Q2 2022

Aug 15, 2022

BUY
$230.71 - $256.74 $420,122 - $467,523
1,821 Added 115.4%
3,399 $827,000
Q1 2022

May 12, 2022

BUY
$219.27 - $242.57 $103,933 - $114,978
474 Added 42.93%
1,578 $382,000
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $219,563 - $251,270
1,104 New
1,104 $248,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $154B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Quantinno Capital Management LP Portfolio

Follow Quantinno Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantinno Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantinno Capital Management LP with notifications on news.